Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.79 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200760 | 0.88 | EGLN1 (1.00) | EGLN1ALDH1A1 | |
| SCHEMBL2204239 | 0.87 | EGLN1 (0.83) | EGLN1HTTALDH1A1 | |
| SCHEMBL12697382 | 0.82 | EGLN1 (0.79) | EGLN1ALDH1A1KMT2A | |
| SCHEMBL2201947 | 0.82 | EGLN1 (0.79) | EGLN1ALDH1A1 | |
| SCHEMBL2206131 | 0.82 | EGLN1 (1.00) | EGLN1TSHRALDH1A1 | |
| SCHEMBL7685030 | 0.82 | EGLN1 (0.74) | EGLN1HPGDALDH1A1MMP13KDM4E | |
| SCHEMBL7690780 | 0.82 | EGLN1 (0.77) | EGLN1ALDH1A1KMT2A | |
| SCHEMBL7954600 | 0.81 | EGLN1 (0.80) | EGLN1ALDH1A1 | |
| SCHEMBL7535584 | 0.80 | USP2 (0.68) | HTTUSP2HPGDTSHRALDH1A1 | |
| SCHEMBL2201315 | 0.80 | EGLN1 (1.00) | EGLN1HPGDALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105168213-A | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA | 2015-12-23 | — | — | CN | claimed |
| US-8969380-B2 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA (LU) | 2015-03-03 | — | — | US | claimed |
| EP-2519503-B1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM SA (LU) | 2013-10-23 | — | — | EP | claimed |
| US-20120329797-A1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM SA (LU) | 2012-12-27 | — | — | US | claimed |
| EP-2519503-A1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM S.A. (LU) | 2012-11-07 | — | — | EP | claimed |
| CN-102712597-A | Secondary 8-hydroxyquinoline-7-carboxamide derivatives as antifungal agents | POLICHEM SA | 2012-10-03 | — | — | CN | claimed |
| EP-2345642-A1 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM S.A. (LU) | 2011-07-20 | — | — | EP | claimed |
| CN-105168213-A | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA | 2015-12-23 | — | — | CN | disclosed |
| US-8969380-B2 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA (LU) | 2015-03-03 | — | — | US | disclosed |
| US-8969380-B2 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA (LU) | 2015-03-03 | — | — | US | disclosed |
| US-8969380-B2 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM SA (LU) | 2015-03-03 | — | — | US | disclosed |
| EP-2519503-B1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM SA (LU) | 2013-10-23 | — | — | EP | disclosed |
| US-20120329797-A1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM SA (LU) | 2012-12-27 | — | — | US | disclosed |
| US-20120329797-A1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | POLICHEM SA (LU) | 2012-12-27 | — | — | US | disclosed |
| CN-102712597-A | Secondary 8-hydroxyquinoline-7-carboxamide derivatives as antifungal agents | POLICHEM SA | 2012-10-03 | — | — | CN | disclosed |
| EP-2345642-A1 | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | POLICHEM S.A. (LU) | 2011-07-20 | — | — | EP | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | EGLN1 3964/4885HTT 4096/4885USP2 2524/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | EGLN1 1953/4885HTT 3598/4885USP2 3538/4885 |
| US-20120329797-A1 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES FOR USE AS ANTIFUNGAL AGENTS | ERG28, TUBA8, CYP51A1 | EGLN1 1246/4885HTT 3722/4885USP2 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.